Petri Dishes

Recent News

March 2020

aTen Therapeutics relocates to new offices at 1 Lochrin Square, Fountainbridge, Edinburgh EH3 9QA.

August 2019

Ian Abercrombie appointed Chief Executive Officer at aTen Therapeutics.

July 2019

aTen Therapeutics welcomes Kimberley Meredith on a summer work placement via the University of Edinburgh.

Overview

Our management team has extensive experience within the biopharmaceutical industry, and a wealth of knowledge in building successful biotechnology companies.

The team was responsible for the formation and subsequent growth of Bioenvision Inc. into a NASDAQ National listed, global biopharmaceutical company, which was acquired by Genzyme Corporation in October 2007.

This experienced management team is now applying its expertise to the growth of aTen Therapeutics and the development of Tensinomab as a new medicine with the potential to treat several serious medical conditions.

A subsidiary of OncoBioPharm Ltd, aTen Therapeutics has recently completed a financing round which will take lead candidate Tensinomab through to clinical trials.

info@atentherapeutics.com

© aTen Therapeutics 2020. All rights reserved